MedtechLedger currently links 310 FDA records to the applicant name Medtronic, Inc.. The collection includes 11 510(k) clearances. It includes 11 original PMA approvals. 70 entries are PMA supplements. 218 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Mar 14, 1988 to Nov 8, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NVZ appears in 40 of the 310 linked filings. The collection spans 28 FDA product codes and 29 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P960009, with 40 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 31 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 7000 Central Ave., NE, Minneapolis, MN, 55432. Recorded on P960009/S545, decision dated Nov 8, 2026.
FDA approved a supplement to PMA P960009, not a new whole-system approval. The record ties S545 to the Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense (B32000), and the stated change is limited to a size change for the lead insertion tool.
The decision text also names a change in tip width dimension verification testing, but it does not supply the original measurement, the revised measurement, or any clinical rationale. The supplement type is listed as Real-Time Process, with a Process Change - Manufacturer/Sterilizer/Packager/Supplier reason.
FDA approval-order wording
approval for dimensions size change for lead insertion tool and modification to tip width dimension verification testing.
FDA lists this action as a 30-Day Notice supplement to PMA P130021/S188 for Medtronic’s Evolut FX delivery catheter system within the Evolut FX transcatheter aortic valve system. The database record frames it as a process change, not a new PMA and not a new approval of the whole system.
The only changed item described in the supplied text is “the introduction of an automated vision system for the detection of flash.” The record does not say what “flash” refers to, where the vision system is used in the manufacturing chain, or whether any device design, indication, or clinical evidence changed.
FDA approval-order wording
the introduction of an automated vision system for the detection of flash
The FDA recorded a 30-Day Notice decision coded OK30 on 2026-10-30 for P960009/S548, a supplement to Medtronic, Inc.'s Activa Deep Brain Stimulation Therapy System, Percept PC BrainSense. The device category is an implanted electrical stimulator for parkinsonian tremor, classified under product code MHY in the Neurology specialty. The supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier.
The recorded scope covers three manufacturing changes: adding a new surface mount technology production line, revising the SMT process sequence so automated optical inspection follows each SMT assembly stage, and adding an equivalent solder paste inspection system plus a qualified de-paneling machine for PCBA production. This action concerns production process and equipment only; it is not an approval of the whole system, and no clinical, efficacy or labeling conclusions follow from the record. The source lists no documents, so inspection criteria, validation data and line qualification details remain unknown.
FDA approval-order wording
approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production
FDA lists this as supplement P860004/S465 to the SynchroMed Infusion System, Ascenda Intrathecal Catheters PMA. The decision is a 30-Day Notice for a process change, so the record describes manufacturing changes tied to the existing approved system rather than a new approval of the whole device.
The specific changes are a new surface mount technology production line, a revised SMT process sequence with automated optical inspection after each SMT assembly stage, and added solder paste inspection plus a qualified de-paneling machine for PCBA production. The source does not provide clinical data, a new indication, or device performance results; it only states the manufacturing scope of the notice.
FDA approval-order wording
approval for the following three changes: 1) Adding a new surface mount technology (SMT) production line.2) Revision of the SMT manufacturing process sequence to perform automated optical inspection immediately following each SMT assembly stage.3) Addition of an equivalent solder paste inspection system and addition of a qualified de-paneling machine for PCBA production
The FDA recorded decision OK30 on 2026-10-29 for PMA supplement P980035/S849, submitted by Medtronic, Inc. as a 30-Day Notice. The supplement covers a series of battery electrolyte fill manufacturing process updates at Medtronic Energy and Components Center, filed under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The affected devices are the Astra S DR, Astra S SR, Astra XT DR, Astra XT SR, Azure S DR and Azure S SR MRI implantable pulse generators, classified as permanent implantable pulse generators (product code NVZ) in the cardiovascular specialty.
The supplement modifies a manufacturing step for the battery component rather than the pulse generator system as a whole, and the record does not establish a new approval of the complete device. The source data do not include the supplement documents, the specific electrolyte formulation or fill parameters changed, any performance testing, or the basis for the OK30 decision. Whether the updated process affects battery behavior in clinical use is not addressed in the available record.
Readers should treat this as a dated administrative record of a process change and not as evidence of changed clinical performance or labeling.
FDA approval-order wording
a series of battery electrolyte fill manufacturing process updates at Medtronic Energy and Components Center
Oct 29, 2026 · 30-Day Notice
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
RECALL COVERAGE
Recalls linked to this firm
MedtechLedger links 14 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 14 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.
Z-2810-2026 · FDA links K260195 · Recalling firm: MEDTRONIC PERFUSION SYSTEMS
Z-2811-2026 · FDA links K260195 · Recalling firm: MEDTRONIC PERFUSION SYSTEMS
Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.